Stock Worth Mentioning: Caladrius Biosciences Inc Stock Is At Yearly Low Now

Stock Worth Mentioning: Caladrius Biosciences Inc Stock Is At Yearly Low Now

The stock of Caladrius Biosciences Inc (NASDAQ:CLBS) hit a new 52-week low and has $3.68 target or 11.00% below today’s $4.14 share price. The 7 months bearish chart indicates high risk for the $24.54M company. The 1-year low was reported on Oct, 17 by If the $3.68 price target is reached, the company will be worth $2.70 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 18,741 shares traded hands. Caladrius Biosciences Inc (NASDAQ:CLBS) has declined 54.63% since March 14, 2016 and is downtrending. It has underperformed by 60.24% the S&P500.

Analysts await Caladrius Biosciences Inc (NASDAQ:CLBS) to report earnings on November, 3. They expect $-1.22 earnings per share, up 41.90% or $0.88 from last year’s $-2.1 per share. After $-1.33 actual earnings per share reported by Caladrius Biosciences Inc for the previous quarter, Wall Street now forecasts -8.27% EPS growth.

Caladrius Biosciences Inc (NASDAQ:CLBS) Ratings Coverage

Out of 4 analysts covering Caladrius Biosciences (NASDAQ:CLBS), 2 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 50% are positive. Caladrius Biosciences has been the topic of 7 analyst reports since August 7, 2015 according to StockzIntelligence Inc. Benchmark maintained it with “Hold” rating and $1 target price in Friday, January 8 report. The firm earned “Buy” rating on Tuesday, December 22 by Maxim Group. The firm has “” rating by Benchmark given on Friday, August 7. The firm earned “Neutral” rating on Friday, January 8 by H.C. Wainwright. The stock of Caladrius Biosciences Inc (NASDAQ:CLBS) has “Buy” rating given on Tuesday, August 23 by Chardan Capital Markets. The firm earned “Buy” rating on Friday, April 29 by H.C. Wainwright. The rating was downgraded by Maxim Group to “Hold” on Thursday, January 7.

According to Zacks Investment Research, “Caladrius Biosciences, Inc. is an immunotherapy company which specializes in cell process optimization, development and manufacturing. Its product candidate consists of NBS20, a targeted cancer immunotherapy product for the treatment of metastatic melanoma; NBS10, an ischemic repair product to preserve heart muscle function following an acute myocardial infarction and NBS03D, an immune modulation product for the treatment of diabetes which are in different clinical trials. Caladrius Biosciences, Inc., formerly known as NeoStem, Inc., is headquartered in New York.”

More notable recent Caladrius Biosciences Inc (NASDAQ:CLBS) news were published by: which released: “Caladrius Biosciences Inc.” on June 08, 2015, also with their article: “Caladrius Biosciences, Inc. Enters Into Agreements To Raise $25 Million in …” published on September 15, 2016, published: “News Caladrius Biosciences Inc.CLBS” on June 09, 2015. More interesting news about Caladrius Biosciences Inc (NASDAQ:CLBS) were released by: and their article: “Caladrius Biosciences Receives FDA Fast Track Designation for CLBS03 to Treat …” published on July 28, 2016 as well as‘s news article titled: “Caladrius Biosciences to Present at Upcoming October Conferences” with publication date: October 04, 2016.

CLBS Company Profile

Caladrius Biosciences, Inc., formerly NeoStem, Inc., incorporated on October 18, 1980, through its subsidiary, PCT, LLC, a Caladrius Company (PCT), provides development and manufacturing services to the cell therapy industry (which includes cell gene therapy). PCT specializes in cell and cell gene therapies. PCT offers development and manufacturing capabilities, quality systems, cell and tissue processing, logistics, storage and distribution and engineering solutions to clients with therapeutic candidates at all stages of development. The Company’s product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs. This therapy is based on a platform technology for immunomodulation.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment